Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1075 | 1049 | 1178 | 1080 | 1441 | 1497 |
Fund Return | 7.46% | 4.89% | 17.8% | 2.6% | 7.57% | 4.12% |
Place in category | 349 | 465 | 327 | 190 | 347 | 256 |
% in Category | 43 | 57 | 48 | 33 | 53 | 64 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
American Funds NVIT Asset Allocatio | 6.47B | 6.37 | 3.14 | 7.26 | ||
NVIT SP 500 Index Fund Class II | 2.4B | 11.06 | 9.04 | 12.15 | ||
American Funds NVIT Growth Fund II | 1.79B | 11.29 | 6.26 | 14.89 | ||
NVIT Investor Destinations Balance2 | 1.15B | 3.44 | 0.80 | 4.47 | ||
Nationwide Institutional Service | 1.14B | 11.35 | 8.23 | 11.76 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Intl Stock Index Inv | 197.89B | 6.01 | 0.42 | 4.22 | ||
Vanguard Total Intl Stock Index Adm | 75.61B | 6.04 | 0.47 | 4.29 | ||
Fidelity International Index Inst | 50.5B | 7.74 | 3.30 | 4.80 | ||
Fidelity Series Global ex US Index | 45.8B | 6.35 | 0.53 | 4.10 | ||
Vanguard Total Intl Stock Index I | 41.01B | 6.06 | 0.50 | 4.32 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 2.55 | 993.5 | -1.10% | |
ASML Holding | NL0010273215 | 2.23 | 965.90 | +1.22% | |
Nestle | CH0038863350 | 1.70 | 92.52 | +0.70% | |
AstraZeneca | GB0009895292 | 1.39 | 12,086.0 | -1.77% | |
Shell | GB00BP6MXD84 | 1.37 | 34.06 | +0.52% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Strong Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review